BioTech
PFE

Pfizer agrees to pay $345 mln to resolve EpiPen pricing lawsuit

Credit: REUTERS/BRIAN SNYDER

Pfizer Inc has agreed to pay $345 million to resolve claims by consumers who claim they overpaid for EpiPens due to anticompetitive and unfair practices by the drugmaker and the company that markets the emergency allergy treatment, Mylan.

Adds details, comments

July 15 (Reuters) - Pfizer Inc PFE.N has agreed to pay $345 million to resolve claims by consumers who claim they overpaid for EpiPens due to anticompetitive and unfair practices by the drugmaker and the company that markets the emergency allergy treatment, Mylan.

The proposed class action settlement was disclosed in a filing in federal court in Kansas City, Kansas. The deal, which requires a judge's approval, would not resolve claims against Mylan, which is scheduled to face trial in January.

Paul Geller, a lawyer for the plaintiffs, said they were "pleased that Pfizer resolved its part of this class action lawsuit over the pricing of EpiPens."

Pfizer, which did not admit wrongdoing, did not immediately respond to a request for comment.

The EpiPen is a handheld device that treats life-threatening allergic reactions by automatically injecting a dose of epinephrine.

The litigation followed a public outcry in 2016 after Mylan, which owns the rights to market and distribute the devices, raised the price of a pair of EpiPens to $600, from $100 in 2008, putting it in the center of an ongoing U.S. debate over the high cost of medicines.

The lawsuit accused Mylan and Pfizer, which manufactured the EpiPen for Mylan, of engaging in anticompetitive conduct that allowed them maintain a monopoly over the market for the devices and their profitable revenues.

The settlement came after U.S. District Judge Daniel Crabtree last month dismissed much of but not all of the claims against Mylan.

The remaining antitrust claims concern a patent settlement the plaintiffs say delayed the launch of a generic epinephrine auto-injector. Mylan has said it "firmly believes that Mylan's conduct was lawful and pro-competitive."

Mylan in 2017 agreed to pay $465 million to resolve U.S. Justice Department claims it overcharged the government for the EpiPen.

(Reporting by Nate Raymond in Boston; Editing by Kim Coghill)

((Nate.Raymond@thomsonreuters.com and Twitter https://twitter.com/nateraymond; 347-243-6917; Reuters Messaging: nate.raymond.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PFE

Other Topics

Markets US Markets

Latest BioTech Videos

    This Drug Has the Potential to Become the First FDA-Approved on-Demand Treatment for Social Anxiety

    VistaGen Therapeutics CEO Shawn Singh discusses a drug that has the potential to become the first FDA-approved on-demand treatment for social anxiety.

    5 days ago

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More